Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
topline save search
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
Published: 2024-04-18 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | News | $1.51 -5.63% -5.96% 270K
|
|
| O: -0.63%
H: 1.89%
C: -4.4%
neurology presentation readout positive topline meeting
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE | News | $42.16 1.35% 1.33% 1.3M
|
Finance
|
| O: 0.78%
H: 0.0%
C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
OCUL | News | $5.86 -22.69% -29.35% 6.1M
|
Health Technology
|
| O: -5.78%
H: 0.0%
C: 0.0%
ocular positive for topline diabetic
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $13.03 3.66% 3.53% 1.8M
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
New Topline Efficacy Data from the enVVeno Medical VenoValve® Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
Published: 2024-04-16 (Crawled : 15:00) - hancockjaffe.com
NVNO | $4.9 2.08% 2.04% 36K
|
Manufacturing
|
| O: -1.22%
H: 0.0%
C: -2.06%
venovalve symposium topline medical trial
New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
NVNO | $4.9 2.08% 2.04% 36K
|
Manufacturing
|
| O: -1.22%
H: 0.0%
C: -2.06%
symposium topline medical trial
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
ITCI | News 0 d | $72.01 -6.1% -6.5% 4.7M
|
Health Technology
|
| O: 14.75%
H: 12.75%
C: 6.04%
positive topline therapy results study
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
VIRX | $0.8971 -4.18% -4.36% 79K
|
Manufacturing
|
| O: -12.71%
H: 0.97%
C: -24.27%
t-cell positive topline trial therapeutics results
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
Published: 2024-04-11 (Crawled : 19:00) - globenewswire.com
ENLV | $1.42 -4.05% -4.23% 92K
|
Health Technology
|
| O: 3.28%
H: 2.12%
C: -16.4%
topline trial results
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
Published: 2024-04-11 (Crawled : 12:00) - globenewswire.com
ENLV | $1.42 -4.05% -4.23% 92K
|
Health Technology
|
| O: -44.19%
H: 1.36%
C: -17.19%
topline trial results
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
Published: 2024-04-09 (Crawled : 13:00) - biospace.com/
ALKS | $23.78 -0.96% -0.97% 1.8M
|
Health Technology
|
| O: 4.48%
H: 0.82%
C: -2.05%
narcolepsy positive topline results study
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.73%
H: 2.49%
C: 0.11%
abrysvo disease positive risk for rsv results study
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
INZY | $4.57 -1.72% -1.75% 560K
|
Health Technology
|
| O: 2.2%
H: 7.69%
C: -9.69%
inz-701 pharma positive ongoing trials topline
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:30) - globenewswire.com
EFTR | $1.775 -6.09% -6.48% 140K
|
|
| O: -76.55%
H: 13.89%
C: -17.78%
lung cancer cell topline trial therapeutics results
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
Published: 2024-04-02 (Crawled : 22:00) - globenewswire.com
FGEN | $1.165 -8.27% -9.01% 1.3M
|
Health Technology
|
| O: -0.93%
H: 0.47%
C: -31.31%
fg-3246 cancer topline results study
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
Published: 2024-04-01 (Crawled : 19:00) - biospace.com/
EQ | $1.77 -1.12% -1.13% 74K
|
Health Technology
|
| O: -1.73%
H: 0.0%
C: -7.05%
lupus positive topline study
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
Published: 2024-04-01 (Crawled : 12:30) - globenewswire.com
VIRX | $0.8971 -4.18% -4.36% 79K
|
Manufacturing
|
| O: 0.96%
H: 8.57%
C: 5.71%
congress topline trial therapeutics results
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
Published: 2024-03-26 (Crawled : 21:00) - globenewswire.com
ZVRA | $4.51 -2.8% -2.88% 260K
|
n/a
|
| O: 1.22%
H: 3.11%
C: 2.59%
kp1077 trial therapeutics
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
Published: 2024-03-26 (Crawled : 12:30) - globenewswire.com
INZY | $4.57 -1.72% -1.75% 560K
|
Health Technology
|
| O: 2.09%
H: 14.47%
C: 6.6%
inz-701 pharma report ongoing trials topline
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
Published: 2024-03-26 (Crawled : 12:00) - globenewswire.com
SLS | $1.505 6.74% 6.31% 1.6M
|
Health Technology
|
| O: 1.92%
H: 2.83%
C: 0.0%
sls009 positive update topline aml study
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.